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Abstract
Background
Preterm birth (PTB) is a leading cause of neonatal mortality and longer-term morbidity.
Acute chorioamnionitis (ACA) is a common cause of PTB, however, there are limited data
on the prevalence of ACA and its association with PTB in resource limited settings.
Methods
Data and samples came from a clinical trial evaluating novel strategies for the prevention of
malaria in HIV infected pregnant women in Uganda. Women were enrolled between 12–28
weeks of gestation and followed through delivery. For each placenta delivered, three pla-
cental tissue types (membrane roll, umbilical cord and chorionic plate/villous parenchyma)
were collected. Slides were assessed for diagnosis of maternal and fetal ACA by micro-
scopic evaluation of neutrophilic infiltration using a standardized grading scale. The primary
outcomes were PTB (<37 weeks), low birth weight (LBW, <2500 grams), and small-for-ges-
tational age (SGA, birth weight <10th percentile for age). Univariate and multivariate logistic
regression were used to estimate associations between 1) maternal characteristics (age,
education, wealth, gravidity, gestational age at enrollment, placental malaria, anti-malarial
prophylaxis treatment regimen, HIV disease parameters) and ACA, and 2) associations
between ACA and adverse birth outcomes.
Findings
A total of 193 placentas were included in the analysis. The prevalence of maternal and fetal
ACA was 44.5% and 28.0%, respectively. HIV infected women between 28–43 years of age
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had a higher risk of maternal ACA compared to those between 17–21 years of age (50.9%
vs. 19.1%; aOR = 4.00 (1.10–14.5), p = 0.04) and the diagnosis of severe maternal ACA
was associated with a significantly higher risk of PTB (28.6% vs. 6.0%; aOR = 6.04 (1.87–
19.5), p = 0.003), LBW (33.3% vs. 9.4%; aOR = 4.86 (1.65–14.3); p = 0.004), and SGA
(28.6% vs. 10.1%; aOR = 3.70 (1.20–11.4), p = 0.02). No maternal characteristics were sig-
nificantly associated with fetal ACA and the diagnosis of fetal ACA was not associated with
adverse birth outcomes.
Conclusions
Histological evidence of severe maternal ACA was associated with an increased risk of
PTB, LBW, and SGA in HIV infected, pregnant Ugandan women.
Introduction
Preterm birth (PTB, delivery occurring prior to 37 weeks) and low birth weight (LBW, weight
<2500 grams) are major determinants of infant mortality and morbidity during childhood [1,
2]. PTB is a leading cause of death among neonates [3], complications arising from PTB are
the leading cause of mortality among children less than five years of age worldwide [4], and
PTB can result in long term neurodevelopmental difficulties for surviving children [5]. PTB is
often associated with LBW, and LBW is an important stand-alone risk factor for infant death
[3]. Rates of PTB range from 5–18% of live neonates [5], with the highest incidences reported
in sub-Saharan Africa and South Asia [3, 5]. The United States Agency for International Devel-
opment (USAID) cooperative agreement project to combat PTB and LBW in Africa and Asia
recently estimated that, in Uganda, approximately 226,000 babies are born preterm every year
and 12,500 deaths occur as a direct consequence of prematurity [6].
While the pathologic trigger for the majority of PTB cases is unknown, the most commonly
identified trigger of PTB is acute chorioamnionitis (ACA) [7, 8]. ACA is defined as the mater-
nal and/or fetal inflammatory response to microbial infection of the amniotic sac [9, 10]. Most
ACA cases are caused by bacterial or fungal organisms that ascend to the placenta from the
lower genital tract, while a minority of infections occur secondary to seeding of the uterus
from the maternal bloodstream or from direct abdominal extension [11]. Obstetricians diag-
nose “clinical” ACA when characteristic maternal symptoms, such as fever and tenderness, are
present [11]. However, some infections may progress sub-clinically [12]. Therefore, gold stan-
dard diagnosis is made during microscopic examination of the placenta, and this has often
been referred to as “histologic” ACA [9, 10]. In response to infection, maternal and fetal acute
inflammatory cells (maternal and fetal neutrophils, and fetal eosinophils) exit vasculature to
infiltrate the placental membranes (chorioamnion), umbilical cord, and chorionic plate. The
neutrophil response is such that there is stereotyped progression of neutrophil and eosinophil
location and cell density [10], and there is both high accuracy and inter-observer concordance
for diagnosing the presence of inflammation and grading the severity [9].
It is possible that the susceptibility to ACA and the pathogenesis of placental infection
in Uganda might be altered by the presence of other infections endemic to this location,
notably HIV and malaria. According to the joint United Nations Programme on HIV/AIDS
(UNAIDS), greater than 600,000 Ugandan women are HIV seropositive [13]. Despite the ben-
efits of antiretroviral medication in pregnancy, some evidence suggests a moderate association
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of protease inhibitor treatment with increased PTB [14], and HIV status itself may be a risk
factor for PTB [15]. We recently published a study that showed an association between placen-
tal malaria (PM) and poor birth outcomes (PTB and LBW) in the same Ugandan cohort ana-
lyzed here [16], and Abrams et al found that both HIV seropositivity and histologic ACA were
risk factors for PTB in malaria-exposed women in Malawi [17]. While some evidence from
Malawi links PM to PTB [18], another study from the same country did not observe such an
association [17]. Thus, the correlation between these infections, treatment regimens, and poor
birth outcomes has not been conclusively studied.
Further, little is known about the prevalence of ACA and associated risk factors in Uganda.
A single study in South Western Uganda identified histologic ACA in 34.1% of women deliv-
ering at full term gestation [19]. Unfortunately, this study did not examine placentas from pre-
term deliveries, and microscopic evaluation was limited to the placental membranes and did
not include the umbilical cord and chorionic plate, two locations that are important to exam-
ine in order to avoid false negative diagnosis. To better understand the epidemiology of ACA
in Uganda, we undertook a study to assess the prevalence of histologic ACA in HIV infected
pregnant Ugandan women and to evaluate the association between ACA and the risk of
adverse birth outcomes (PTB, LBW, and SGA). Although not all known risk factors for ACA
and adverse outcomes were assessed, several important maternal factors associated with ACA
were examined. Such assessments are important for improving obstetrical practice policies
and preventive measures in Uganda and similar resource-limited settings.
Materials and methods
Study design, site and participant population
Clinical data and biological samples for this study came from a double-blinded randomized
clinical trial (Registration number NCT02282293) evaluating intermittent preventive therapy
for malaria in pregnancy (IPTp) among HIV infected women in Tororo, Uganda [20]. Two
hundred HIV infected pregnant women at least 16 years of age were enrolled at 12–28 weeks
gestational age, between December 2014 to November 2015, and were randomized to daily tri-
methoprim-sulfamethoxazole (TMP-SMX) plus monthly dihydroartemisinin-piperaquine
(DP) or daily TMP-SMX alone [20]. The study physician estimated gestational age using last
menstrual period and fetal measurements obtained by a standardized abdominal ultrasound
exam. All women were provided with combination antiretroviral therapy (ART) consisting of
Efavirenz (EFV)/tenofovir/lamivudine. Women received routine HIV care per the Uganda
Ministry of Health guidelines, and HIV-1 RNA monitoring was additionally performed. Par-
ticipants were prospectively followed until delivery, at which point the placenta was harvested
and prepared (as described below) for microscopic examination and diagnosis of ACA.
Study procedures and follow up
At enrollment, a long-lasting insecticide treated net was provided to every participant and a
detailed history including a household questionnaire and physical assessment/examination
was obtained. Study participants were closely monitored throughout pregnancy by monthly
assessments and collection of blood samples, and all their health care needs were provided by a
dedicated study clinic open seven days a week. Participants were encouraged to deliver at the
hospital. However, in the event of a home or other health facility delivery, participants were
visited by the study staff at the time of delivery or as soon as possible afterwards.
Upon delivery, a comprehensive assessment of birth outcomes was made, including neona-
tal evaluation for congenital anomalies, measurement of birth weight and gestational age. All
placental sampling was done within 30 minutes of delivery. Placental specimens were fixed in
Acute chorioamnionitis and the risk of adverse birth outcomes in Uganda
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10% Neutral Buffered Formalin for 24 hours, and stored at room temperature in 70% ethanol
prior to tissue processing. The following placental tissues were collected: placental membranes
(“membrane roll”), umbilical cord (two cross-sectional slices, one proximal and one distal to
where the cord inserts into the placental disc), chorionic plate with villous parenchyma, and
basal plate with villous parenchyma. The basal plate/villous parenchyma section was used for
diagnosis of PM in our separately reported studies [16, 20, 21], while the other three sections
(membrane roll, umbilical cord, chorionic plate/villous parenchyma) were used as described
below for the diagnosis of ACA in the study reported here.
Laboratory methods
For microscopic diagnosis of ACA, three placental specimens were utilized: membrane roll,
umbilical cord, and chorionic plate/villous parenchyma. In the Tororo, Uganda laboratory,
specimens were dehydrated through a series of ethanol washes, cleared in xylene and embed-
ded in paraffin wax blocks. A 3 μm thick section from each tissue block was obtained using a
rotary microtome and sections mounted onto glass slides via a floatation water bath. Slides
were baked in a hot air oven at 60˚C for 30 minutes, de-paraffinized in xylene, dehydrated
through a series of ethanol washes, stained with Hematoxylin and Eosin (H&E), and mounted
with organic mounting media.
Diagnosis of ACA was made by standard light microscopic examination (Nikon Eclipse Ci-
L microscope with DS-Ri2 color camera) of the three placental biopsy slides (membrane roll,
umbilical cord, and chorionic plate/villous parenchyma) (Fig 1). Diagnosis of a maternal acute
inflammatory response to infection (“maternal ACA”) was indicated by detection of neutro-
phils within the chorioamnion layers of the membrane roll and/or the chorionic plate. Diagno-
sis of a fetal acute inflammatory response to infection (“fetal ACA”) was indicated by detection
of neutrophils with or without eosinophils within the vascular smooth muscle of the umbilical
cord vessels and/or the chorionic plate vasculature [9]. Diagnosis was rendered in blinded
fashion by a placental pathologist (G.R.) and noted on a standardized case record form.
Grading of maternal ACA and fetal ACA was assigned using the standardized diagnostic
framework of the Perinatal Section of the Society for Pediatric Pathologists [9]. Grade was
recorded on the case record form as either: no evidence of ACA, mild (scattered mostly single,
isolated neutrophils), moderate (small clusters of neutrophils) and severe (presence of neutro-
philic microabscesses). Specifically, severe maternal ACA was defined as the presence of
microabscesses measuring greater than or equal to 10 x 20 neutrophils in extent, and present
within at least three foci, or with neutrophils present as a contiguous band. Severe fetal ACA
was defined as the presence of near confluent intramural neutrophils with attenuation/degen-
eration of vascular smooth muscle cells.
Variables of interest
The maternal characteristics examined included: maternal age and gestational age at enroll-
ment, education, household wealth index, and gravity. Maternal characteristics pertaining to
malaria included: IPTp regimen (either TMP-SMX plus DP or TMP-SMX alone), and evi-
dence of PM defined by histopathology. Additionally, the following maternal characteristic
pertaining to HIV infection were assessed: duration since HIV diagnosed, duration since ART
was begun, WHO HIV stage at enrollment, CD4 T-cell count at delivery, and viral load at
delivery. None of the women enrolled were WHO HIV stage 4 (defined as AIDS). ACA was
categorized as maternal ACA (the presence of maternal acute inflammation, defined above)
and fetal ACA (the presence of fetal acute inflammation, defined above). Maternal and fetal
ACA were each categorized into a grading scale: none/mild, moderate and severe (defined
Acute chorioamnionitis and the risk of adverse birth outcomes in Uganda
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above). The birth outcomes assessed were PTB (delivery at<37 weeks), LBW (birth weight
<2500 grams, and SGA (birth weight <10th percentile for age).
Statistical analysis
Data were coded, double entered into a Microsoft access database and analyzed using Stata 14
(Stata Corp, College Station TX). Participants’ baseline maternal characteristics were expressed
as means ± SD for continuous variables, while categorical variables were expressed as propor-
tions. Univariate and multivariate logistic regression were used to 1) measure associations
between maternal characteristics and maternal and fetal ACA, and 2) measure associations
between maternal and fetal ACA and the risk of adverse birth outcomes. P values < 0.05 were
Fig 1. Representative placental histology. (A&B) Normal umbilical cord. �indicates lumen of umbilical vessels. (C) Umbilical vein with heavy neutrophilic infiltrate
(arrows point to aggregates of neutrophils) and early degeneration of smooth muscle cells diagnostic of severe fetal ACA. (D) Normal chorionic plate/villous
parenchyma. Arrow indicates the chorionic plate, and � indicates lumen of a fetal chorionic plate vessel. (E) Chorionic plate with heavy neutrophilic infiltrate in the
walls of a fetal chorionic plate vessel (severe fetal ACA) and neutrophils in the subchorionic fibrin layer (maternal ACA). Arrows point to aggregates of neutrophils.
(F&G) Normal membrane roll. (H) Membrane roll with neutrophilic microabscess diagnostic of severe maternal ACA (arrows point to neutrophils). In G and H,
{-bracket indicates amnion, [-bracket indicates chorion, and arrow indicates decidua parietalis. Scale bars are 1 mm (panels A, D, F) and 200 μM (panels B, C, E, G, H).
https://doi.org/10.1371/journal.pone.0215058.g001
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considered statistically significant. Measures of association in both univariate and multivariate
models were expressed as odds ratios (OR) or adjusted odds ratios (aOR) and respective 95%
confidence intervals (CI). Gravidity was not included in the final multivariate model due to
correlation with maternal age.
Ethical approval
All study participants provided informed written consent. Ethical approval was obtained from
the Uganda National Council of Science and Technology (UNCST #HS 1708), Makerere Uni-
versity School of Medicine Research and Ethics Committee, the Makerere University School of
Biomedical Sciences Research and Ethics Committee (#SBS-REC 159), and the University of
California, San Francisco, Committee on Human Research (CHR #14–13900).
Results
Maternal characteristics of study participants
A total of 200 HIV infected pregnant women were enrolled and followed through delivery,
and 194 placenta samples were collected. A total of 191 and 193 placental samples were suc-
cessfully assessed for maternal and fetal ACA, respectively, and included in the analysis as
shown in Fig 2. A majority of the women were 28–43 years old age (61.7%), completed primary
level of education (55.4%), and were multigravida (78.8%), while only 4.7% had evidence of
PM diagnosed by histopathology (Table 1). At enrollment, most women had been on combi-
nation ART for>90 days (67.4%), and were WHO HIV disease stage 1 (asymptomatic)
(94.8%). At delivery, a majority of the women showed a normal CD4 T-cell count (61.7%), and
only 23.8% had detectable HIV virus.
Prevalence of ACA in HIV infected pregnant women
Overall, microscopic exam revealed that 102/193 (52.8%) of women were diagnosed with
either maternal and/or fetal ACA. Maternal ACA was diagnosed in 44.5% of samples (22.5%
Fig 2. Participant trial profile. Summary of placental samples acquired.
https://doi.org/10.1371/journal.pone.0215058.g002
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mild, 11.0% moderate and 11.0% severe), while fetal ACA was observed in 27.9% of the sam-
ples (17.6% mild, 9.3% moderate and 1.0% severe).
Associations between maternal characteristics and ACA
Associations between maternal characteristics and the diagnosis of maternal ACA are shown
in Table 2. Only one statistically significant association was identified in multivariate analysis.
Table 1. Maternal characteristics among samples with any assessment for ACA.
Characteristic Prevalence
Age categories at enrollment
17–21 years 21 (10.9%)
22–27 years 53 (27.5%)
28–43 years 119 (61.7%)
Highest level of formal education
None 43 (22.3%)
Primary school 107 (55.4%)
Secondary school 25 (13.0%)
Beyond secondary school 18 (9.3%)
Household wealth index
Lowest tertile 64 (33.2%)
Middle tertile 62 (32.1%)
Highest tertile 67 (34.7%)
Gravidity
Primigravida 18 (9.3%)
Secundigravida 23 (11.9%)
Multigravida 152 (78.8%)
Gestational age at enrollment
12–16 weeks 51 (26.4%)
16–20 weeks 53 (27.5%)
20–24 weeks 54 (28.0%)
24–28 weeks 35 (18.1%)
Duration since HIV first diagnosed at enrollment
>5 years 62 (32.2%)
2–5 years 55 (28.5%)
6 months–2 years 37 (19.2%)
� 6 months 39 (20.2%)
Duration on ART at enrollment
>90 days 130 (67.4%)
1–90 days 25 (13.0%)
Started on ART at time of enrollment 38 (19.7%)
WHO HIV disease stage 2 or 3 at enrollment 10 (5.2%)
IPTp regimen during pregnancy
Daily TMP-SMX 95 (49.2%)
Daily TMP-SMX + monthly DP 98 (50.8%)
CD4 T cell count at delivery
>500 cells/mm3 119 (61.7%)
250–500 cell/mm3 58 (30.1%)
<250 cells/mm3 16 (8.3%)
Detectable HIV viral load at delivery 46 (23.8%)
Placental malaria by histopathology at delivery 9 (4.7%)
https://doi.org/10.1371/journal.pone.0215058.t001
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Older age at enrollment was associated with increased odds of maternal ACA, with women
28–43 years of age having ~4 times the odds of maternal ACA compared to those 17–21 years
of age in multivariate analysis (aOR = 4.00 (1.10–14.5), p = 0.04). Regarding the two different
IPTp regimens, there was a lower prevalence of maternal ACA in women maintained on
TMP-SMX plus DP versus TMP-SMX alone, but this association was of borderline statistical
significance (aOR = 0.57 (0.31–1.06), p = 0.07).
No significant associations were observed between maternal ACA and formal education,
household wealth index, or gestational age at enrollment. Additionally, no significant associa-
tions were observed between maternal ACA and the documented HIV disease/treatment char-
acteristics (duration since HIV diagnosis, duration of ART, WHO stage of HIV disease, CD4
T-cell count at delivery, or viral load at delivery).
As shown in Table 3, there were no statistically significant associations between maternal
characteristics and the diagnosis of fetal ACA.
Table 2. Associations between maternal characteristics and any evidence of maternal ACA.
Characteristic Category Risk of any maternal ACA Univariate Multivariate
OR (95% CI) p-value aOR (95% CI) p-value
Age in years at enrollment 17–21 4/21 (19.1%) reference reference
22–27 21/52 (40.4%) 2.88 (0.85–9.77) 0.09 2.64 (0.71–9.86) 0.15
28–43 60/118 (50.9%) 4.40 (1.40–13.9) 0.01 4.00 (1.10–14.5) 0.04
Formal education Any 63/148 (42.6%) reference reference
None 22/43 (51.2%) 1.41 (0.72–2.79) 0.32 1.15 (0.53–2.51) 0.73
Household wealth index Lowest third 25/63 (39.7%) reference reference
Middle third 28/61 (45.9%) 1.29 (0.63–2.63) 0.48 1.19 (0.55–2.56) 0.66
Highest third 32/67 (47.8%) 1.39 (0.69–2.79) 0.35 1.53 (0.70–3.35) 0.29
Gravidity Multigravida 69/151 (46.4%) reference Not included in final model
due to correlation with
maternal age
Secundigravida 9/22 (40.9%) 0.82 (0.33–2.04) 0.67
Primigravida 7/18 (38.9%) 0.76 (0.28–2.06) 0.58
Gestational age at enrollment > 20–28 weeks 34/88 (38.6%) reference reference
> 16–20 weeks 25/53 (47.2%) 1.42 (0.71–2.82) 0.32 1.23 (0.58–2.58) 0.59
12–16 weeks 26/50 (52.0%) 1.72 (0.85–3.47) 0.13 1.29 (0.59–2.86) 0.52
Duration since HIV diagnosed � 2 years 28/75 (37.3%) reference reference
> 2years 57/116 (49.1%) 1.62 (0.90–2.93) 0.11 1.36 (0.64–2.87) 0.42
When started on ART > 90 days before enrollment 59/129 (45.7%) reference reference
1–90 days before enrollment 9/25 (36.0%) 0.67 (0.27–1.62) 0.37 0.96 (0.34–2.70) 0.94
At enrollment 17/37 (46.0%) 1.01 (0.48–2.10) 0.98 1.82 (0.72–4.61) 0.21
WHO stage at enrollment Stage 1 82/181 (45.3%) reference reference
Stage 2–3 3/10 (30.0%) 0.52 (0.13–2.06) 0.35 0.26 (0.05–1.30) 0.10
IPTp regimen TMP-SMX alone 49/94 (52.1%) reference reference
TMP-SMX + DP 36/97 (37.1%) 0.54 (0.30–0.97) 0.04 0.57 (0.31–1.06) 0.07
CD4 T-cell count at delivery > 500 cells/mm3 56/118 (47.5%) reference reference
250–500 cells/mm3 21/57 (36.8%) 0.65 (0.34–1.23) 0.19 0.72 (0.36–1.45) 0.36
< 250 cells/mm3 8/16 (50.0%) 1.11 (0.39–3.15) 0.85 1.91 (0.52–7.00) 0.33
Viral load at delivery Undetectable 70/145 (48.3%) reference reference
Detectable 15/46 (32.6%) 0.52 (0.26–1.04) 0.07 0.55 (0.24–1.23) 0.15
Placental malaria Absent 83/182 (45.6%) reference reference
Present 2/9 (22.2%) 0.34 (0.07–1.69) 0.19 0.75 (0.12–4.71) 0.76
https://doi.org/10.1371/journal.pone.0215058.t002
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Associations between ACA and adverse birth outcomes
After adjusting for maternal age, multivariate analysis showed that women with evidence of
severe maternal ACA had a significantly higher risk of PTB (28.6% vs. 6.0%; aOR = 6.04 (1.87–
19.5), p = 0.003), LBW (33.3% vs. 9.4%; aOR = 4.86 (1.65–14.3), p = 0.004), and SGA (28.6%
vs. 10.1%; aOR = 3.70 (1.20–11.4), p = 0.02) compared to women with no ACA or only mild
maternal ACA (Table 4). There was no significant association between evidence of fetal ACA
(moderate or severe vs. none/mild) and the risk of adverse birth outcomes.
Discussion
High prevalence of ACA in HIV infected Ugandan cohort
Our study determined the prevalence of ACA in pregnant HIV infected Ugandan women and
evaluated for associations between ACA and the risk of three adverse birth outcomes (PTB,
LBW, and SGA). The overall prevalence of ACA was 52.8%, maternal ACA was more fre-
quently diagnosed than fetal ACA, and most cases were of mild severity. While these patterns
Table 3. Associations between maternal characteristics and any evidence of fetal ACA.
Characteristic Category Risk of any fetal ACA Univariate Multivariate
OR (95% CI) p-value aOR (95% CI) p-value
Age in years at enrollment 17–21 5/21 (23.8%) reference reference
22–27 17/53 (32.1%) 1.51 (0.47–4.81) 0.49 1.39 (0.39–4.91) 0.61
28–43 32/119 (26.9%) 1.18 (0.40–3.48) 0.77 1.59 (0.46–5.47) 0.46
Formal education Any 45/150 (30.0%) reference reference
None 9/43 (20.9%) 0.62 (0.27–1.39) 0.25 0.47 (0.19–1.17) 0.11
Household wealth index Lowest third 18/64 (28.1%) reference reference
Middle third 17/62 (27.4%) 0.97 (0.44–2.11) 0.93 0.95 (0.41–2.19) 0.90
Highest third 19/67 (28.4%) 1.01 (0.47–2.17) 0.98 0.89 (0.39–2.06) 0.79
Gravidity Multigravida 44/152 (29.0%) reference Not included in final model due
to correlation with maternal ageSecundigravida 7/23 (30.4%) 1.07 (0.41–2.79) 0.88
Primigravida 3/18 (16.7%) 0.49 (0.14–1.78) 0.28
Gestational age at enrollment > 20–28 weeks 21/89 (23.6%) reference reference
> 16–20 weeks 17/53 (32.1%) 1.53 (0.72–3.26) 0.27 1.75 (0.76–4.02) 0.19
12–16 weeks 16/51 (31.4%) 1.48 (0.69–3.19) 0.32 2.05 (0.84–5.00) 0.12
Duration since HIV diagnosed � 2 years 25/76 (32.9%) reference reference
> 2years 29/117 (24.8%) 0.67 (0.36–1.27) 0.22 0.70 (0.32–1.54) 0.38
When started on ART > 90 days before enrollment 33/130 (25.4%) reference reference
1–90 days before enrollment 9/25 (36.0%) 1.65 (0.67–4.10) 0.28 1.49 (0.52–4.25) 0.46
At enrollment 12/38 (31.6%) 1.36 (0.62–2.99) 0.45 1.23 (0.48–3.17) 0.67
WHO stage at enrollment Stage 1 54/183 (29.5%) reference reference
Stage 2–3 0/10 (0%) NA - NA -
IPTp regimen TMP-SMX alone 31/95 (32.6%) reference reference
TMP-SMX + DP 23/98 (23.5%) 0.63 (0.34–1.19) 0.16 0.56 (0.28–1.10) 0.09
CD4 T-cell count at delivery > 500 cells/mm3 38/119 (31.9%) reference reference
250–500 cells/mm3 11/58 (19.0%) 0.50 (0.23–1.07) 0.07 0.51 (0.23–1.16) 0.11
< 250 cells/mm3 5/16 (31.3%) 0.97 (0.31–2.98) 0.96 2.05 (0.52–8.10) 0.31
Viral load at delivery Undetectable 39/147 (26.5%) reference reference
Detectable 15/46 (32.6%) 1.34 (0.65–2.74) 0.42 1.46 (0.63–3.38) 0.37
Placental malaria Absent 52/184 (28.3%) reference reference
Present 2/9 (22.2%) 0.73 (0.15–3.61) 0.70 1.16 (0.18–7.16) 0.87
https://doi.org/10.1371/journal.pone.0215058.t003
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(maternal inflammation more common than fetal inflammation, most cases of mild severity)
are consistent with textbook ACA literature drawn from numerous studies in resource rich
settings [22], the prevalence we describe is higher than what has been reported for resource
rich settings (20% of term deliveries and approximately 50% of preterm deliveries) [23].
Our results help to fill a gap in the literature regarding placental pathology for this under-
studied patient population. A single prior study in Uganda identified histologic ACA in 34%
of 136 placentas delivered at term and evaluated at the Mbarara Regional Referral Hospital
[19]. Nearly all women (91.5%) in the Mbarara study were HIV negative. Other notable differ-
ences between our analysis and this prior report include our larger cohort that included all
deliveries not just those delivered at term gestation, and our microscopic examination was
more extensive. Unfortunately, comparing and contrasting different studies is difficult unless
identical delivery and diagnostic criteria are utilized. Both the inclusion of pre-term deliveries
and the more comprehensive microscopic examination would be expected to show a higher
prevalence of ACA and thus this might explain why our study showed such, when compared
to the previous Ugandan cohort study. Indeed, a recent study that utilized similar diagnostic
criteria to ours documented a similarly high prevalence of histologic ACA in both HIV
infected (61.6%) and HIV uninfected (57.1%) Nigerian women [24].
Strengths and weaknesses
Strengths of this study include the moderately large cohort size, that the diagnosis was ren-
dered by a trained placental pathologist according to the criteria recommended by the Society
for Pediatric Pathology [9], and that slides were examined in blinded fashion.
However, we acknowledge certain weaknesses and caveats in both the study design and
analysis. All participants resided within a small region of Uganda, thus the findings may not
generally represent the entire population. Although our samples size was relatively large com-
pared to previous studies, statistical power was relatively limited to provide precise estimates
of measures of association for the socio-demographic and biological risk factors assessed. Fur-
thermore, we only examined a select set of maternal characteristics, which unfortunately did
not include several factors associated with the adverse outcomes PTB, LBW, and SGA. Impor-
tant risk factors for adverse outcomes that were not included in our analysis are maternal
stress, prolonged rupture of membranes, duration of labor, previous history of PTB, and medi-
cal conditions (such as pre-eclampsia) during pregnancy [25–27]. On the other hand, our
Table 4. Associations between maternal or fetal ACA and adverse birth outcomes.
Location Intensity Preterm birth (< 37 weeks) Low birthweight (< 2500 grams) Small-for-gestational age
Risk of outcome aORa (95% CI) p-value Risk of outcome aORa (95% CI) p-value Risk of outcome aORa (95% CI) p-value
Maternal
ACA
None-
mild
9/149 (6.0%) reference 14/149 (9.4%) reference 15/149 (10.1%) reference
Moderate 3/21 (14.3%) 2.43 (0.59–
9.99)
0.22 2/21 (9.5%) 1.02 (0.21–
4.92)
0.98 1/21 (4.8%) 0.45 (0.05–
3.63)
0.45
Severe 6/21 (28.6%) 6.04 (1.87–
19.5)
0.003 7/21 (33.3%) 4.86 (1.65–
14.3)
0.004 6/21 (28.6) 3.70 (1.20–
11.4)
0.02
Fetal ACA None-
mild
17/173 (9.8%) reference 23/173 (13.3%) reference 22/173 (12.7%) reference
Moderate 1/18 (5.6%) 0.50 (0.06–
4.05)
0.52 0/18 (0%) NA - 0/18 (0%) NA -
Severe 0/2 (0%) NA - 0/2 (0%) NA - 0/2 (0%) NA -
a adjusted for maternal age
https://doi.org/10.1371/journal.pone.0215058.t004
Acute chorioamnionitis and the risk of adverse birth outcomes in Uganda
PLOS ONE | https://doi.org/10.1371/journal.pone.0215058 April 11, 2019 10 / 15
study did carefully assess many important maternal characteristics, including HIV disease
stage and treatment regimen.
We must also note that our analysis did not include assessment for clinical ACA, nor did
we assess for pathogenic causes of ACA (versus “sterile inflammation”) in our samples.
Regarding this latter point, while ACA was historically believed to correlate well with micro-
bial infection [22], recent work has in fact suggested that a majority of term deliveries diag-
nosed with histologic ACA might in fact be “noninfectious” [28]. However, such conclusion
must be based upon a truly exhaustive search for pathogens (bacterial, fungal, and viral) and
even then it may be impossible to rule out recent past infection that then resolved. Future
work with a larger cohort that combines careful histologic and clinical diagnosis of ACA with
all known maternal risk factors for both ACA and adverse outcomes should be the next step.
Maternal risk factors associated with histologic ACA
Often cited maternal risk factors associated with a diagnosis of ACA include nulliparity, youn-
ger maternal age, prolonged labor, prolonged rupture of membranes, multiple vaginal exams,
internal fetal monitoring, bacterial vaginosis, and Group B streptococcus (GBS) colonization
[12, 19, 23, 25, 26, 29]. Unfortunately, our study did not include evaluation for bacterial vagi-
nosis or GBS colonization, nor was there documentation of labor duration and number of vag-
inal exams. The association between older maternal age and increased risk for ACA identified
in our study was surprising because this differs from the established literature. Indeed, text-
books and reviews report an association between younger maternal age and ACA [22, 23].
Interestingly, two recent studies examining risk factors for histologic ACA in preterm and
spontaneous term delivery did not find a significant association with young maternal age [29,
30]. Thus, future studies should continue to test for associations between ACA and maternal
age, since our findings suggest that different patient populations may show different risk
factors.
Intriguingly, we observed a trend towards a reduction in ACA risk for women taking
TMP-SMX plus DP compared to TMP-SMX alone. This raises the possibility that malarial che-
moprevention regimens might in fact alter the susceptibility to and/or pathogenesis of other
infectious agents. Indeed, TMP-SMX has a broad antimicrobial spectrum that includes placen-
tal pathogens Listeria monocytogenes, Escherichia coli, as well as many urinary tract pathogens
noted to be associated with increased risk for ACA [31, 32]. To our knowledge, whether the
artemisinin-based compound DP, which is effective against malaria [20, 21, 33] and schistoso-
miasis [34], has antibacterial/fungal properties has not been described, however this may war-
rant future investigation.
Greater than 600,000 Ugandan women are HIV seropositive [13], and HIV infection and
treatment may alter the susceptibility and/or immune response to acute chorioamnionitis.
Indeed, numerous reports document increased maternal-to-fetal transmission of HIV in the
setting of genital and placental co-infections, including chorioamnionitis [35, 36]. The data
from our study show no significant association between maternal HIV disease characteristics
and diagnosis of ACA. However, it is important to acknowledge that the majority of women
were WHO stage 1 (asymptomatic), with normal CD4 T-cell counts and undetectable viral
loads at delivery. Future studies are needed to thoroughly examine whether HIV is a risk factor
for ACA.
Association of maternal ACA with poor birth outcome
Our data showed a significant association between severe maternal ACA and PTB, a finding
which is consistent with extensive prior work identifying ACA as a significant risk factor for
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PTB [7, 8, 12, 17, 37]. There was also an increased risk of LBW and SGA among women with
severe maternal ACA, when compared to the combined cohort of women with no evidence of
maternal ACA and women with only mild ACA. These data complement those of a recent
study evaluating clinical and pathologic characteristics of mothers and placentas from 38 LBW
deliveries in Nigeria, where histologic ACA was identified in a high percentage (44%) of such
deliveries [38].
There was no significant association between fetal ACA and the risk PTB or LBW. This is
somewhat surprising, as fetal ACA is also a well-established risk factor for PTB [7, 8, 12, 17,
37]. The prevalence of PTB in our study (10.2%) was not unusually low, however there were
very few cases of severe fetal ACA (only two cases). Previous studies have correlated an associ-
ation between severe fetal ACA and neurological impairment including cerebral palsy [39, 40].
Our study did not include assessment of such for the newborns.
Finally, we recently reported that placental malaria diagnosis was not associated with a
higher risk of adverse birth outcome for the same HIV infected cohort analyzed here for ACA
[20]. These results are consistent with that of a prior study in Malawi where ACA but not PM,
was found to be associated with a higher risk for PTB [17]. In our current assessment of ACA
and risk factors, we did not identify a significant association between ACA and PM. Additional
study is required to better define the risk factors for adverse birth outcomes within populations
of pregnant of women that are exposed to pathogens not endemic to areas where the bulk of
the prior placental pathology literature has focused. Such studies might shed light on interplay
among organisms, prophylactic medications, and treatment regimens that alter the biology of
preterm and term labor.
Future investigations
Microbial induced PTB is largely believed to be an inflammatory process where immune medi-
ators disrupt uterine quiescence, culminating in parturition [41, 42]. While delivery of the
infected placenta confers a benefit to the mother, sadly, this host defense mechanism comes at
the price of prematurity, and all the short and long-term consequences thereof. Studies have
found that ACA is mostly polymicrobial in nature, with aerobic and anaerobic commensals
from other body sites (gut, vaginal, oral, urinary tract) often implicated [10, 11]. The causative
microbes for ACA in resource-limited settings, including Uganda, have yet to be studied. Pre-
delivery testing of pregnant woman for GBS carrier status with administration of penicillin to
those who test positive is routine clinical practice in the United States, but is not currently part
of clinical practice in many resource-limited settings, including our Ugandan population. The
potential benefit of such testing and treatment is currently unknown, and thus the incidence
of GBS and other placental pathogens within the Ugandan population should be the topic of
future investigation. Notably, GBS is the leading cause of neonatal meningitis in Malawi [43],
and one report showed microbiologic culture evidence of GBS is some stillbirths associated
with ACA in Zimbabwe [44]. Thus, we hope that our current work will serve as the platform
for further investigation into the nature of ACA, as well as other placental pathologies, in
Uganda and other understudied populations.
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